What is IPF Phase III ASCEND (pirfenidone)?

Category: Others

true

Generic name: Pirfenidone

The ASCEND trial is a randomized, double-blind, placebo-controlled, study of the efficacy and safety of pirfenidone in Idiopathic Pulmonary Fibrosis. NCT01366209

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
2
None
1

Commonly reported side effects and conditions associated with IPF Phase III ASCEND (pirfenidone)

Side effect Patients
Decreased appetite 1
Diarrhea 1
Dizziness 1
Headaches 1
Increased sleepiness 1
Indigestion 1

Show all 14 reported side effects

Dosages

Based on patients currently taking IPF Phase III ASCEND (pirfenidone)

Dosage Patients
267 mg daily 1
200 mg three times daily 1

Duration

Currently taking IPF Phase III ASCEND (pirfenidone)

Duration Patients
1 - 2 years 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 3
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 3
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 3
Not specified 0
Last updated:
There are no evaluations for IPF Phase III ASCEND (pirfenidone).